Clinical Trial Update: A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) [Phase 2]

View source ↗

Summary

This Phase 2 trial (KEYNOTE-799) evaluated pembrolizumab in combination with chemotherapy and radiotherapy for stage III non-small cell lung cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-11-02